JIANGSU HENGRUI MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.27 CNY | +1.33% |
|
-1.21% | -4.33% |
| 05-27 | China Grants Clinical Trial Approval for Anti-Cancer Injections | MT |
| 05-22 | Hengrui Pharma Gets China Drug Registration Certificate for Ovarian, Fallopian Tube Cancer Drugs | MT |
Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products:
- anti-tumor drugs (No. 1 Chinese);
- Anesthetic drugs;
- contrast agents: used in medical imaging;
- anti-inflammatory drugs;
- drugs for the treatment of cardiovascular diseases.
Sector
Pharmaceuticals
Calendar
18/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
43.27
CNY
Average target price
57.57
CNY
Spread / Average Target
+33.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.33% | 37.48B | |
| +38.59% | 727B | |
| -7.89% | 354B | |
| +15.66% | 328B | |
| +0.24% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +4.23% | 164B | |
| -1.70% | 164B |
- Stock Market
- Equities
- 600276 Stock
- News Jiangsu Hengrui Medicine Co., Ltd.
- Hengrui Pharmaceuticals Unit Gets China Clinical Trial Approval for Kidney Medication
